Skip to main content
GALTGalectin Therapeutics Inc.Hold4.2·$3.73
GALT · Why this verdict

Why Galectin Therapeutics (GALT) is rated HOLD

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictHOLD
Overall score4.2/10
ConfidenceMEDIUM
MacroNEUTRAL

Per-dimension breakdown

Value

5.0/10data confidence 50%

Quality

0.6/10data confidence 100%
ComponentSub-score
ROA0.0
Gross margin0.0
Op margin0.0
Net margin0.0
Current ratio0.4
FCF quality0.0
Moat4.5
Piotroski F0.0
  • Cash-burning (FCF negative)
  • No competitive moat
  • Weak Piotroski F-Score: 0/9
  • Quality concerns

Growth

5.0/10data confidence 50%

Momentum

2.4/10data confidence 100%
ComponentSub-score
RSI5.5
MACD2.6
OBV1.0
MA position3.0
Volume0.0
  • Volume distribution (falling OBV)
  • Above 200-MA but MA slope flat

Sentiment

6.6/10data confidence 100%
ComponentSub-score
Analyst rating5.0
Price target10.0
erm sentiment5.0
  • Analyst upside: 195%

Insider

5.9/10data confidence 100%
ComponentSub-score
materiality4.5
insider conviction2.0
holder change10.0
notable moves7.0
  • Modest insider selling — $107,013 (0.029% of mkt cap)
  • Institutions accumulating

Peer rank

5.0/10data confidence 80%
ComponentSub-score
value rank5.0
quality rank5.0
growth rank5.0

Technical

5.2/10data confidence 100%
ComponentSub-score
bollinger7.4
support resistance7.7
52w position0.5
gap5.0

Risk (lower is worse)

3.5/10data confidence 80%
ComponentSub-score
short interest4.1
days to cover0.0
volatility0.0
beta10.0

Catalyst

2.8/10data confidence 100%
ComponentSub-score
erm5.0
earnings history0.0
surprise avg0.0
news activity6.0
  • Earnings concerns: 1B/3M

How the verdict was assembled

Engine trigger

Market cap $371M below $400M minimum. Not in investable universe.

Engine technical detail
verdict_path: L1:HARD_BLOCK:MARKET_CAP
Passed (7)
  • ASYMMETRY:10.0>=1.5
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:NO_DATE
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
  • MOMENTUM:2.4<4.5
Warning (0)

none

Reward-to-Risk
10.02
Upside
+150.3%
Downside
15.0%
Sizing output
AVOID

Setup No clear chart pattern; technical signals are mixed

EdgeNo clear edge No clear edge identified

SuitabilitySpeculative Drawdown -48% (>40% off 52w high), Binary industry: Biotechnology

Investment implication

The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 2.4<4.5 outcome against Sentiment at 6.6 and asymmetric R:R of 10.02.

The strongest dimensions are Sentiment at 6.6, Insider at 5.9, and Technical at 5.2; the weakest are Quality at 0.6, Momentum at 2.4, and Catalyst at 2.8. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 10.02 and an engine sizing output of AVOID.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home Stocks GALT Why this verdict